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Abstract 
LRIG3 is a member of mammalian LRIG family 
and less is known about the functions of LRIG3. 
Accumulating evidences showed that LRIG3 may 
also function as a tumor suppressor like LRIG1. 
LRIG3 can inhibit tumor cell proliferation, survival, 
adhesion and invasion in many types of human 
cancer cells based on cell experiments. Perinuclear 
staining of LRIG3 correlated with better survival in 
astrocytic tumors. Decreased LRIG3 was identified 
as one of 12 promising serum biomarkers for early 
stage non-small-cell lung cancer. LRIG3 may play 
a role in inner ear morphogenesis and neural crest 
formation. 
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Identity 
Other names: LIG3 
HGNC (Hugo): LRIG3 
Location: 12q14.1 
DNA/RNA 
Description 
According to Entrez-Gene, LRIG3 gene maps to 
NC_000012.12 in the region between 58872155 
and 58920538 and spans across 48.3 kilobases. 
LRIG3 gene is encoded on the reverse strand. 
Transcription 
Homo sapiens leucine-rich repeats and 
immunoglobulin-like domains 3 has at least two 
transcript variants. The pre-mRNAs comprise 19 
exons. The coding sequence of transcript variant 1 
(NM_001136051.2) and 2 (NM_153377.4) is 
3691bp and 4110bp respectively. 
Protein 
Description 
LRIG3 is a transmembrane cell-surface protein 
consisting of 1059 or 1119 amino acids. LRIG3 
contains a signal peptide, 15 tandem LRR with 
cysteine rich N- and C-flanking domains, three 
immunoglobulin-like domains, a transmembrane 
domain, and a cytoplasmic tail. 
Expression 
LRIG3 is ubiquitously expressed in human organs. 
The highest expression of LRIG3 is in stomach, 
thyroid, and skin. 
Localisation 
Differential subcellular expression in a cell type-
sepcific manner. 
Function 
LRIG3 may function as a tumor suppressor. 
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LRIG3 protein. SP: signal peptide; NF: N-terminal cysteine-rich flanking domain; LRRs: 15 leucine-rich repeats; CF: C-terminal 
cysteinerich flanking domain; Ig C2: C2-type immunoglobulin-like domains; TM: transmembrane domain; Cyto: cytoplasmic 
domain. 
 
 
Mutations 
Note 
Mutations in LRIG3 are rare, according to the 
TCGA data set. 
Implicated in 
Ependymoma 
Note 
Perinuclear staining of LRIG3 was significantly 
lower in posterior fossa ependymomas than in 
supratentorial ependymomas (Yi et al., 2009). 
Pituitary adenoma 
Note 
The expression of LRIG 3 in HP75 cell line was 
lower compared to normal pituitary glands (Guo et 
al., 2007). 
Astrocytic tumors 
Note 
Perinuclear expression of LRIG3 in astrocytic 
tumors has been associated with better patient 
survival (Guo et al., 2006).  
Down-regulation of LRIG3 expression in 
glioblastoma cell lines resulted in increased 
proliferation and invasion, decreased apoptosis, and 
increased EGFR expression (Cai et al., 2009). 
Cervical adenocarcinoma 
Note 
High fraction of LRIG3-positive cells were 
significantly associated with patient survival, and 
LRIG3 staining intensity was positively correlated 
with HPV status (Muller et al., 2013). 
Non-small-cell lung cancer 
Note 
LRIG3 downregulation was identified as one of 12 
promising serum biomarkers for early stage non-
small-cell lung cancer (Ostroff et al., 2010). 
Abnormal protein 
The LRIG3-ROS1 fusion has been identified in 
non-small-cell lung cancer (Cai et al., 2013). 
 
 
Psoriasis 
Note 
The expression pattern of LRIG3 protein was 
altered in psoriatic lesions compared to normal skin 
(Karlsson et al., 2008). 
Inner ear morphogenesis 
Note 
During inner ear development, Lrig3 acts to repress 
Netrin transcription and Lrig3 loss led to defects in 
inner ear morphogenesis (Abraira et al., 2008). 
Neural crest formation 
Note 
LRIG3 is required for neural crest formation in 
developing Xenopus embryos by regulating the 
Wnt and Fgf signaling pathways (Zhao et al., 
2008). 
To be noted 
Note 
Recently, Colleen Sweeney and Lisa V Goodrich 
reported that overexpression of LRIG3 in 
HEK293T cells increased the ERBB receptor 
expression (Rafidi et al., 2013). However, 
downregulation of LRIG3 in a human glioblastoma 
cell line, GL15, resulted in upregulation of total 
EGFR and phospho-EGFR, and enchanced glioma 
cell proliferation, adhesion and invasion (Cai et al., 
2009).  
Therefore, the precise function of LRIG3 in regard 
to ERBB receptor signalling modulation may be 
context-dependent and the role of LRIG3 needs to 
be further studied. 
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